Theon International: Investor Webcast on July 9 Following the Acquisition of HGH for €300M
Theon International will host an investor webcast on July 9 to detail its financial strategy and recent developments, including the acquisition of HGH Systèmes Infrarouges for approximately €300M. This presentation comes two weeks before the announcement of its second-quarter results.
A Web Conference to Clarify Trajectory and HGH Acquisition
The Greek manufacturer of thermal imaging and night vision systems will host a session on July 9 at 11 AM (British time) for dialogue with investors via the Investor Meet Company platform. Philipe Mennicken, Deputy CEO and Director of Business Development, and Dimitris Parthenis, Chief Financial Officer, will present recent developments and the financial outlook of the group. This intervention will also discuss the recently announced strategic acquisition of SAS Stéropès, the holding company controlling HGH Systèmes Infrarouges.
The webcast will include a live Q&A session and will welcome current and potential investors, as well as other market participants. Questions can be submitted before the event or live during the session via the platform.
A Major Acquisition to Strengthen Thermal Offering
Theon International has reached an agreement to acquire SAS Stéropès for an enterprise value of approximately €300M. This transaction involves HGH Systèmes Infrarouges, a provider of thermal imaging systems. The acquisition aligns with the group's development objectives, which already operates in more than 10 countries and has over 280,000 systems in service with armed and specialized forces in 72 countries, including 26 NATO members.
In 2025, Theon won the largest public tender for night vision goggles in the history of a NATO member state, a contract for more than 100,000 units for the Belgian and German armed forces, valued at approximately €1 billion.
